Advertisement
Advertisement
U.S. markets open in 1 hour 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.81-0.06 (-0.40%)
At close: 04:00PM EDT
14.81 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Sign in to post a message.
  • p
    peter
    Well, all I can say is it is very rare to see this kind of rate of tumor shrinkage in heavily pretreated patients in P1s for non chemotherapies in solid tumors, with very low toxicity.
    Quite impressive really. The shorts are talking about time to approval being 3 years. Not with these rates of response. This will get approved based on ORR out of registrational P2, if the data hold up and the DOR is decent.
  • f
    freddy
    Reuters news on 20 August that Merus filed for US mixed shelf offering for up to USD 250 million. This news somehow does not reach yahoo. Merus is a promising biotech but this ought to be known to investors more broadly. Not sure based on SEC filing how much they will add to share count and terms. Dillution usually not a good thing, cash position should be enough. Awating more info I say at the sidelines for a while.
  • A
    Anonymous
    Up 5.4% without any news. That's the way thinly traded small caps roll.
  • S
    S
    Market CORRECTION starts any days, do not hold your long positions.🔊🔊
    with a over 30% stock market crash coming next 4 to 5 because infrastructure bill
    and$ 3.5trillion bill wont get sign in 2021 will cause a USA economic recovery delayed and stalled for 15 months and no jobs created ,stock market reaction will be very very scary scary over30pluspercentcrash to the stock market
  • A
    Anonymous
    News about MCLA - 145 (monoclonal antibody)being co-developed with INCY.
  • B
    Bechody
    “S” must be in great pain as the more he shorts, they higher this climbs and the longer he hold, the more he losses.
    Bullish
  • B
    Bechody
    30+ by close or AH. Buy with confidence.
    Bullish
  • f
    freddy
    Patent settlement with Regeneron. Latter will buy 600,000 shares in MRUS @ USD 25 per share
    If you notice the low liquidity this stock is just not under the radar of investors, hence the sharp disparity
  • P
    Peter
    volume leads price like I've been saying for a few months (read past posts). Going higher.
  • P
    Pharmanot
    Check out the largest stake by Novo (not to mention BB). Novo knows a good thing when they see it and lost out on the bidding for Ablynx, but MRUS is more valuable in the long run and cheaper.
  • R
    Ryan
    just like all stocks with huge runups, they have to pull back to consolodate or they will crash. I think this will drop $26 in the AH and without any momentum will break 25 in the AM. This could crash much harder without more support.
    Bearish
  • a
    anglesm
    Down day tomorrow -

    Merus N.V. Announces Proposed Public Offering of Common Shares
    November 4, 2021 at 4:07 PM EDT

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Merus intends to use the net proceeds from the offering to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes.

    Jefferies LLC and SVB Leerink LLC are acting as joint book-running managers for the offering. Kempen & Co is acting as lead manager for the offering. H.C. Wainwright & Co. and Roth Capital Partners are acting as co-managers for the offering.

    The offering will be made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (“SEC”) on May 7, 2021 and was effective upon filing....
  • P
    Peter
    getting ready to move up-volume increasing with price
  • C
    Chi
    BVF PARTNERS L P/IL, 10%-Owner of Merus N.V. BOUGHT 1462510 shares on 2020-06-01. https://formwhispers.com/s?t=MRUS
    FormWhispers - Trading Ideas from Insider Merus N.V. MRUS.
    FormWhispers - Trading Ideas from Insider Merus N.V. MRUS.
    formwhispers.com
  • a
    anglesm
    Merus Announces Pricing of Public Offering of Common Shares
    November 4, 2021 at 9:01 PM EDT

    UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 578,947 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters’ option to purchase the Option Shares, are approximately $110.0 million. All of the shares in the offering are to be sold by Merus.

    The offering is expected to close on or about November 9, 2021, subject to customary closing conditions.

    Merus intends to use the net proceeds from the offering to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes.
  • A
    Anonymous
    Expect some "tape painting" the last few trading days of 2017. Should see move near $20.
  • P
    Peter
    love a stock that quietly climbs on no news or broker pumping. Something good is on the horizon. Stay tuned.
    Bullish
  • K
    K
    Is there any news today? Almost 7% increase!
  • S
    S
    News release from Phase-1 clinical result are always 100% positive for any biotech companies
    but once they go into P-2 and P3 studies then the 80% of them are bound to fail. 🤐🤐👎
  • A
    Anonymous
    There is a good chance INCY will buy MRUS lock, stock and barrel for several billion.
Advertisement
Advertisement